UNIVERSITY OF BIRMINGHAM

Type 1 Diabetes

Early Detection Summit

9 - 10 June 2025

Edgbaston Park Hotel
University of Birmingham

Summit Information

Contents

Welcome to the Type 1 Diabetes Early Detection Summit 2025

We are extremely excited to host the first ever **Type I Diabetes Early Detection Summit** in **Birmingham**, UK, on **9-10th June 2025**.

This two-day conference is aimed at practicing healthcare professionals, doctors as well as the wider multidisciplinary team within the UK, and will cover the practicalities of and science underpinning the rapidly changing area of **screening**, **monitoring** and **treatment of early T1D**.

With international renowned speakers, including Marian Rewers (Denver), Emanuele Bosi (Milan), Colin Dayan (Cardiff), this meeting will bring together paediatric and adult diabetes specialists to meet, share ideas, exchange knowledge and research in the emerging field of early T1D.

Sponsors, Exhibitors and Endorsers

Platinum Sponsor

sanofi

Silver Sponsors

Lilly
A MEDICINE COMPANY

RANDOX
BIOSCIENCES

Exhibitors

digostics
DIGITAL DIAGNOSTICS

Endorsers

DIABETES UK
KNOW DIABETES. FIGHT DIABETES.

Breakthrough T1D™
Formerly JDRF

ABCD
Association of British Clinical Diabetologists

Association of Children's Diabetes Clinicians

BSPED
British Society for Paediatric Endocrinology and Diabetes

Diabetes Research & Wellness Foundation

UKT1D
Research Consortium
Moving towards insulin-free T1D

Key Information

Event Address:

Edgbaston Park Hotel

53 Edgbaston Park Rd

Birmingham

B15 2RS

Parking Information

Car parking is free when attending the Edgbaston Park Hotel. The car park is located outside the entrance of the hotel. Please ensure you provide your car registration on entry in the hotel reception.

Refreshments & Lunch

On Monday, refreshments and lunch will be split across the Fry Lounge and the Lloyd Suite. Please see below information for the conference dinner.

On Tuesday, all refreshments and lunch will be in the Fry Lounge.

Conference Registration Opening Times

Conference Registration Desk	Open Times	Location
Monday 9 June	08:00 – 09:00	Lloyd Suite
Tuesday 10 June	08:00 – 09:00	Fry Lounge

Breakout Sessions

Breakout Sessions	Date	Time	Location
a) Running a Pre-symptomatic T1D service in Paediatrics	Monday 9 June	15:30 – 16:30	Lloyd Suite
b) Running a Pre-symptomatic T1D service in adults	Monday 9 June	15:30 – 16:30	Fry Suite

Social Events

Social Event	Date	Time	Location
Welcome Reception	Sunday 8 June	19:00 – 20:30	Composers Suite
Conference Dinner	Monday 9 June	19:00 – 22:00	Fry Suite

Online Streaming

Online Streaming via Zoom	Start & Finish Times
Monday 9 June	09:00 – 15:10
Tuesday 10 June	09:00 – 15:00

Zoom Link

For reference only, we will be using the following Zoom Meeting details:

Link

Meeting ID: 875 1923 5898

Passcode: 937971

Conference Programme

Pre-Summit – Sunday 8 June

Time	Session/Presenter/Topic
19:00 – 20:30	Welcome Reception – Composers Suite

Day 1 – Monday 9 June

Time	Session/Presenter/Topic
08:00 – 09:00	Registration Open
09:00 – 09:10	Welcome
09:10 – 11:00	Screening Programmes Session 1 Chairs: Parth Narendran & Lucy Chambers The Italian Experience - Emanuele Bosi, Milan (09:10 - 09:30) The US Experience - Marian Rewers, Denver, Colorado (09:30 - 09:50) ELSA - Lauren Quinn, Birmingham (09:50 - 10:10) T1DRA - Kathleen Gillespie, Bristol (10:10 - 10:30) Panel discussion on implementing screening in the UK - All speakers, Primary Care Diabetes Society (10:30 - 11:00)
11:00 – 11:30	**COFFEE BREAK**
11:30 – 12:40	How can genetic analysis support the identification of children and adults with pre-symptomatic T1D? – **Richard Oram, Exeter** (11:30 - 11:50) **Research studies into monitoring of Pre-symptomatic T1D** Chairs: Renuka Dias & Emily Simms

	Current UK research Monitoring studies in Children - **Loredana Marcovecchio, Cambridge** (11:50 - 12:10) Current UK Research Monitoring studies in Adults - **Anna Long, Bristol** (12:10 - 12:40)
12:40 – 13:40	**LUNCH**
13:40 – 15:10	Optimising Ab assays for T1D screening - **Alex Richter, Birmingham** (13:40 - 14:00) **Managing Pre-symptomatic T1D in UK clinical practice** Chairs: Fiona Campbell & Danijela Tatovic Monitoring children in UK clinical practice and the UK Ab Registry - **Rachel Besser, Oxford** (14:00 - 14:20) Accurate disease classification and monitoring of Pre-symptomatic T1D in adults - **Nick Thomas, Exeter** (14:20 - 14:40) Panel Discussion with **Marc Atkin** and **Fulya Mehta**, led by **Fiona Campbell**, **Danijela Tatovic** (14:40 - 15:10)
15:10 – 15:30	**COFFEE BREAK**
15:30 – 16:30	**Parallel 'meet the expert' sessions in breakout rooms** a) Running a Pre-symptomatic T1D service in paediatrics (Renuka Dias, Rachel Besser, Emily Simms or b) Running a Pre-symptomatic T1D service in adults Nick Thomas, Parth Narendran, Kimber Simmons
16:30	**CLOSE**
19:00 – 22:00	Conference Dinner – Fry Suite After Dinner Speaker – Partha Kar

Day 2 – Tuesday 10 June

Time	Session/Presenter/Topic
08:00 – 09:00	**Registration and Refreshments** - Fry Lounge
09:00 – 10:50	**Psychosocial Impact** Chair: Olga Boiko The psychological impact of early detection T1D, a summary of evidence so far - **Olga Boiko, Birmingham** (09:00 - 09:20) Prediction and prevention of rheumatoid arthritis: Perspectives of people at risk, patients, and healthcare professionals - **Marie Falahee, University of Birmingham** (09:20 - 09:40) Living with Chronic Uncertainty, examples from Cystic Fibrosis (CFSPID) - **Felicity Boardman, University of Warwick** (09:40 - 10:00) A patient experience of screening - **10 mins for family and adult (ELSA, T1DRA)** (10:00 - 10:30) **Panel discussion with all speakers** (10:30 - 10:50)
10:50 – 11:20	**COFFEE BREAK**
11:20 – 13:00	**Disease Modifying Therapy for T1D** Chairs: Tim Tree & Colin Dayan Lessons from MS - **Gavin Giovannoni, London** (11:20 - 11:40) The US Experience - **Kimber Simmons, Denver** (11:40 - 12:00) The UK Experience - **Renuka Dias, Birmingham** and **Neil Wright, Sheffield** (12:00 - 12:20) Navigating the practicalities of accessing and delivering a 14-day therapy - **Phil Newland Jones, Southampton** (12:20 - 12:40) **Panel Discussion** (12:40 - 13:00)

13:00 – 14:00	**LUNCH**
14:00 – 15:00	**The Future** Chairs: Susan Wong & Rachel Connor Pipeline of DMTs in T1D - **Emily Simms** (14:00 - 14:30) The T1DRC, Platform trials and the future - **Colin Dayan, Cardiff** (14:30 - 15:00)
15:00	**CLOSING REMARKS**

Disclaimer: Sanofi have had no involvement in the agenda/speaker selection or the organisation of the meeting and are involved as an exhibitor only.

Venue Map

Digital Map



Organising Committee

Parth Narendran

Professor of Diabetes Medicine

University of Birmingham, and The Queen Elizabeth Hospital Birmingham

Parth's research interest focusses on understanding the autoimmune destruction of insulin secreting beta cells that lead to type 1 diabetes and exploring how this process can be modulated. He is part of a national effort to explore the feasibility and acceptability of early surveillance programmes for pre-type 1 diabetes and is also exploring which therapies are best tested in the prevention arena. He has developed an international reputation for exploring whether exercise can be used to modulate the autoimmune process in type 1 diabetes. He is the Chair of the MS Prevention Taskforce for the Multiple Sclerosis Society to explore treatment parallels across other conditions with similarities to type 1 diabetes.

Parth leads the Diabetes Research Unit and the Type 1 Diabetes clinical service at the Queen Elizabeth Hospital. He is the author of over 100 peer-reviewed publications including publications that have been cited by international bodies on Type 1 diabetes and its management. He has served on the Diabetes UK Research Committee and was previously on the Research Advisory Board of the Diabetes Research and Wellness Foundation and Regional Advisory Committee for the NIHR RfPB programme. He was previous chair of the Academic subcommittee of The Association of British Clinical Diabetologists having led and supported the setting up of its first research grant funding scheme and national Diabetes Update training programme for doctors specialising in diabetes and endocrinology.

Parth reviews for all the major national and international diabetes journals. He contributes to the NIHR Horizon Scanning, and NICE Medical Technology reviews for new therapies.

Colin Dayan

Professor of Clinical Diabetes and Metabolism

Cardiff University School of Medicine. Senior Clinical Researcher, University of Oxford

Colin Dayan trained in medicine at University College, Oxford, and Guy's and Charing Cross Hospitals in London, UK before obtaining a PhD in the immunology of Graves' Disease in the Laboratory of Marc Feldmann. He then spent a year as an endocrine fellow at the Massachusetts General Hospital in Boston, USA before completing his specialist training in diabetes and endocrinology as a Lecturer in Bristol. In 2010, he was appointed to the Chair of Clinical Diabetes and Metabolism and Head of Section at Cardiff University School of Medicine and in 2020 as part-time Senior Clinical Researcher in the Nuffield Department of Medicine at the University of Oxford.

Prof Dayan has a long-established interest in translational research in the immunopathology of type 1 diabetes promoting progress to "insulin free T1D". He has published first-in-man clinical studies on the development of peptide immunotherapy and the use of nanoparticles in T1D as well as pioneering the use of lymph node and injection site sampling to monitor the response to therapy. Since 2015 he has been a leading member of the UKT1D-Research Consortium which has hosted more than 15 clinical trials in early T1D over 30 sites. He is currently leading on novel trial designs including the T1D Plus platform trial in Europe and Australia to rapidly test combinations of therapies. In collaboration with the Critical Path Institute, he led the TOMI consortium of 21 clinical trials to define the relationship between C-peptide preservation and clinical endpoints and build an FDA/EMA approved clinical trial simulation tool. He is now seeking to define novel endpoints in preclinical T1D as part of the EDENT1FI European programme. Prof Dayan is a committed advocate to finding ways to bring beta cell preservation and delaying the need for insulin therapy into routine clinical practice. In this regard he supported the application for regulatory approval of Tzield to the FDA in 2021 and is working with colleagues to introduce immunotherapy and population screening into the UK.

Renuka Dias

Renuka Dias BMedSci MBBS FRCPCH PhD

Renuka Dias is a Consultant Paediatric Endocrinologist working at Birmingham Women and Children's Hospital and is an Honorary Associate Clinical Professor at the University of Birmingham. She is the Lead for the National Highly Specialised Service for Wolfram Syndrome (Children) in Birmingham. Her research interests include early Type 1 Diabetes including screening (ELSA, EDENT1FI) and delivering disease-modifying treatment in the NHS (NHS FIT) as-well as reducing health outcome inequalities in Type 1 Diabetes (IMPACT1D).

Theodora Papanikolaou

Clinical Research Fellow, University of Birmingham

Theodora Papanikolaou graduated from the School of Medicine, Aristotle University of Thessaloniki, in Greece in 2011. She completed Specialty Training in General Paediatrics in the UK in February 2023 and has since worked as a Senior Clinical Fellow in the Paediatric Endocrinology and Diabetes department at Birmingham Children's hospital.

She current works as a Clinical Research Fellow at the Institute of Immunology and Immunotherapy, based at the University of Birmingham, and is pursuing a MRes (Master of Research) degree.

She is passionate about teaching and quality improvement in healthcare. She is a full instructor for the Advanced Paediatric Life Support (APLS) and Newborn Life Support (NLS) courses.

Lauren Quinn

Clinical Research Fellow, University of Birmingham

Dr Lauren Quinn is a diabetes and endocrinology resident doctor in the West Midlands and a clinical research fellow at the University of Birmingham. She is a PhD candidate and her thesis is testing and developing a general population, paediatric type 1 diabetes screening programme in the UK to explore the feasibility and acceptability of screening.

Keynote Speakers

Marc Atkin

Marc Atkin has been a Consultant in Diabetes, Endocrinology and Internal Medicine in Bath, UK since 2012 and Clinical Lead from 2017-24. He led the establishment of the Bath Integrated Diabetes Service in 2013 which is the longest running in the SW of England. Marc was appointed as the National Specialty Advisor for Diabetes for NHSE England in July 2024. He has been Diabetes Lead of NHS England's Southwest Cardiovascular Clinical Network since 2016. In this time, he has overseen successful implementation of diabetes technology across the region, support of primary care diabetes services including GP diabetes champions and implementation of diabetic foot peer reviews across the SW and beyond.

Marc has also served on various committees across different elements of the NHS system; Association of British Clinical Diabetologists (ABCD) 2016-2019, NHS England's Diabetes Expert Reference Group (2017-2018), Diabetes UK's Diabetes Technology Reference Group (2018-2019), Diabetes UK's Inpatient Care Programme (2018-2020). He has also been one of the leads on the Quality in Care Diabetes Judging Panel since 2016.

Marc is also diabetic foot lead for the Royal United Hospital, Bath and has taken part in a SW Peer Review team that has successfully reduced amputation rates across the Southwest. He has been part of Diabetes UK's National Clinical System Leaders Programme and has served on DUK's Health Professional Advisory Council since 2023.Marc's interests include service development & system leadership, data- driven population health and integration of technology into clinical pathways. He is working on developing clinical pathways that maximise the opportunities offered by diabetes technology. He has also been the Associate Medical Director for Integration for Bath, Swindon & Wiltshire ICS/Acute Hospitals Alliance since 2022. Here he indulges his interests in population health, clinical strategy and operational research.

Rachel Besser

Rachel is a Consultant paediatric endocrinologist at Oxford Children's Hospital and Honorary senior clinical lecturer at the Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, leading the T1Early research programme.

In the UK, Rachel leads the UK Islet Autoantibody registry (www.ukiab.org) for children and adults with one or more islet autoantibodies who do not yet need insulin. The T1Early Programme, focusses on gathering the evidence for screening and early detection in type 1 diabetes (T1D), undertaking work on feasibility, acceptability, cost-effectiveness, and clinical implementation. In Europe, she co-leads the follow up programme in EDENT1FI (www.edent1fi.eu/), a European-wide screening initiative.

Rachel holds a number of senior leadership positions including as Diabetes officer for the British Society for Paediatric Endocrinology and Diabetes (BSPED), Chair of the BSPED Pre-T1D Special Interest group, co-lead of the NHSE Task & Finish group on T1D screening, co-lead of the Oxford NIHR Biomedical Research Centre Metabolic Experimental Medicine theme, and sits on the Management board of the UK Type 1 diabetes Research Consortium. Rachel has led on a number of Pre-T1D consensus guidelines for ISPAD, BSPED and Breakthrough Type 1. She is funded by Diabetes UK, the National Institute of Health Research, and UKRI Horizon Europe. X @BesserBesser @T1Early

Felicity Boardman

Felicity Boardman is a professor of social science and ethics at Warwick Medical School. Her work focuses on the social and ethical aspects of screening programmes, , particularly from the perspectives of screened individuals and their families, and those living with screened-for conditions. She sits on the Foetal, Maternal and Child Health Reference Group of the National Screening Committee, and the Bloodspot Task Group. Her most recent work consists of acceptability studies (newborn screening for spinal muscular atrophy, next generation sequencing in cystic fibrosis newborn screening), as well as a process evaluation of the Generation Study.

Olga Boiko

Olga is an academic medical sociologist with the expertise in process evaluations, implementation research and theories of health and illness. Olga was involved in a wide range of studies set at primary, secondary healthcare interface including doctor-patient interactions, PROM development and implementation, workforce retention, evaluation of research-academic collaborations and NICE guidelines, evaluation of integrated care systems, and quality improvement studies. In 2022-2024 she had an industrial appointment with a consulting company and delivered evidence-based solutions for pharmaceutical companies. Olga's recent interests are coalesced around implementation science, in particular, the acceptability of different interventions (including novel medicines), monitoring tools, guidelines and screening programs. Olga is currently coordinating a Work package within the European research program which aimed at eliciting the impacts of the population screening for Type 1 Diabetes and is also involved in participatory research with disadvantaged communities.

Emanuele Bosi

Emanuele Bosi is a physician, clinician and researcher, currently Full Professor of Internal Medicine and Director of the School of Specialisation in Internal Medicine at Vita Salute San Raffaele University, Milan. Specialised first in Diabetology and later in Clinical Immunology, Emanuele Bosi is a diabetologist, endocrinologist and internist whose research activity has always focused on diabetes.

Trained at the Medical Clinic directed by Prof. Guido Pozza, he worked as a clinical researcher in Lyon on pancreas transplantation, under the direction of Professors Jules Traeger and Jean Michel Dubernard, and later in London on autoimmunity associated with diabetes and Poly endocrinopathies, under the direction of Prof. Gian Franco Bottazzo.

After returning to San Raffaele in Milan, he became Associate Professor of Internal Medicine, then of Endocrinology and later Full Professor, first of Endocrinology and then of Internal Medicine. He is Head of General Medicine with a focus on diabetes and endocrine metabolism, as well as founder and former director of the Diabetes Research Institute (DRI), a translational research institute comprising the clinical and diabetes research facilities at San Raffaele.

Emanuele Bosi's studies have covered several topics of diabetes, in particular aspects of autoimmunity associated with type 1 diabetes, with reference to disease mechanisms and the use of autoantibodies for the definition, prediction and prevention potential of type 1 diabetes. In this context, Emanuele Bosi created at San Raffaele the JDRF International Centre, affiliated to TrialNet, operating from 2004 to 2019, later becoming INNODIA Centre and finally FID-INNODIA. As of 2023, the group is a partner of EDENT1FI. TrialNet, INNODIA and EDENT1FI are international consortia for studying the natural history of type 1 diabetes, screening to identify individuals at risk and conducting interventions aimed at preventing the disease. He has also coordinated several clinical research groups over time, with expertise in conducting trials on the treatment of type 1 diabetes, type 2 diabetes and chronic diabetes complications and on the use of the most advanced technologies in the field of glucose sensors, insulin pumps and integrated systems.

Emanuele Bosi is the author of 225 peer-reviewed scientific publications.

Prof Colin Dayan

Colin Dayan trained in medicine at University College, Oxford, and Guy's and Charing Cross Hospitals in London, UK before obtaining a PhD in the immunology of Graves' Disease in the Laboratory of Marc Feldmann. He then spent a year as an endocrine fellow at the Massachusetts General Hospital in Boston, USA before completing his specialist training in diabetes and endocrinology as a Lecturer in Bristol. In 2010, he was appointed to the Chair of Clinical Diabetes and Metabolism and Head of Section at Cardiff University School of Medicine and in 2020 as part-time Senior Clinical Researcher in the Nuffield Department of Medicine at the University of Oxford.

Prof Dayan has a long-established interest in translational research in the immunopathology of type 1 diabetes promoting progress to "insulin free T1D". He has published first-in-man clinical studies on the development of peptide immunotherapy and the use of nanoparticles in T1D as well as pioneering the use of lymph node and injection site sampling to monitor the response to therapy. Since 2015 he has been a leading member of the UKT1D-Research Consortium which has hosted more than 15 clinical trials in early T1D over 30 sites. He is currently leading on novel trial designs including the T1D Plus platform trial in Europe and Australia to rapidly test combinations of therapies. In collaboration with the Critical Path Institute, he led the TOMI consortium of 21 clinical trials to define the relationship between C-peptide preservation and clinical endpoints and build an FDA/EMA approved clinical trial simulation tool. He is now seeking to define novel endpoints in preclinical T1D as part of the EDENT1FI European programme. Prof Dayan is a committed advocate to finding ways to bring beta cell preservation and delaying the need for insulin therapy into routine clinical practice. In this regard he supported the application for regulatory approval of Tzield to the FDA in 2021 and is working with colleagues to introduce immunotherapy and population screening into the UK.

Renuka Dias

Renuka Dias is a Consultant Paediatric Endocrinologist working at Birmingham Women and Children's Hospital and is an Honorary Associate Clinical Professor at the University of Birmingham. She is the Lead for the National Highly Specialised Service for Wolfram Syndrome (Children) in Birmingham. Her research interests include early Type 1 Diabetes including screening (ELSA, EDENT1FI) and delivering disease-modifying treatment in the NHS (NHS FIT) as well as reducing health outcome inequalities in Type 1 Diabetes (IMPACT1D).

Dr Marie Falahee

Dr Falahee is a psychologist who specialises in research to improve outcomes for immune-mediated inflammatory conditions. Her research on patient preferences for preventive treatments for rheumatoid arthritis is shaping international drug development policy and clinical trial design.

Prof Kathleen Gillespie

Kathleen is Professor of Molecular Medicine at the University of Bristol where she has led the Type 1 Diabetes Research Group since 2014, when she also became Chief Investigator of the long running Bart's Oxford (BOX) family study of type 1 diabetes. She is interested in the mechanisms underlying autoimmunity and the Alistair Williams Antibody Facility in Bristol is an internationally recognised centre for measuring type 1 diabetes risk markers. Current projects include the first natural history study of risk of type 1 diabetes in general population adults (Type 1 diabetes risk in adults - T1DRA), developing new biomarker assays and understanding why children with Down syndrome are at increased risk of autoimmunity.

Prof Gavin Giovannoni

Gavin Giovannoni holds the Chair of Neurology, Blizard Institute, Faculty of Medicine and Dentistry, Queen Mary University London and the Department of Neurology, Barts Health NHS Trust in November. Gavin did his undergraduate medical training at the University of the Witwatersrand, South Africa. His clinical interests are multiple sclerosis and other inflammatory disorders of the central nervous system. He is particularly interested in clinical issues related to optimising MS disease-modifying therapies. His current research focuses on the Epstein-Barr virus as a possible cause of multiple sclerosis and MS prevention.

Dr Naresh Kanumilli

Dr Naresh Kanumilli has been a GP in south Manchester for the past 20 years and he has a specialist interest in diabetes and cardiology. He is a visiting professor-the Institute of Medicine at the University of Greater Manchester at Bolton, as-well as a Diabetes UK Clinical Champion. He is also a consultant in Diabetes at the Manchester University foundation Trust.

Dr Kanumilli has a very keen focus on management of chronic conditions in the community and hence has been actively involved in setting up and running community-based clinics both in cardiology and diabetes. He is actively involved with the current integration agenda to provide patients with seamless care between primary and secondary sectors. He is also keen to ensure that the patients are seen at the right time, in the right place and by the right person. Currently running one of the very few CVRM clinics which provide a holistic one stop service for people living with multiple long-term conditions. He is the Clinical Network Lead for Diabetes across Greater Manchester and East Cheshire and has developed the diabetes strategy for Greater Manchester which is seen as a forerunner for best practice in diabetes care.

He is also the co-author of the document promoting Diabetes care in the PCN structure and is the primary care research lead for Diabetes at the Greater Manchester CRN. Dr Kanumilli is also the Chair of the Primary Care Diabetes Society, which is the largest organisation of Diabetes Professionals in the UK, as-well as being actively involved in education and up skilling of HCP's. He is also a director in the charity Vision Beyond Autism that looks after children and young adults with Autism.

Professor Partha Kar

Partha Kar is the Type 1 Diabetes & Technology lead for NHS England and co-lead of the Getting it Right First Time (Diabetes) and Consultant, Diabetes & Endocrinology in Portsmouth In his role with NHS England some of the highlights have been in leading the expansion of technology in Type 1 Diabetes- namely universal use of Flash Glucose/CGM; CGM in T1D pregnancy, along with the use of online digital self-management platforms. He has also led efforts to collaborate with NICE, ensuring widespread access to Hybrid Closed Loops (HCL) technology, which enables the collection of real-world data. Currently, he is leading a 5-year implementation plan for HCL. This has made the NHS one of the pioneers globally regarding access to technology for those living with Type 1 Diabetes.

Other work has involved developing Language Matters, peer Support networks, as well as Decision Management tools; A comic book series and a TED talk style event- for those living with Type 1 Diabetes He is one of the leading users of social media in diabetes care and writes a monthly blog for the British Medical Journal. He has been the MWRES lead for NHS England 2021-2023 and the author of the 1st Plan to tackle Racism in the Medical Workforce. At present, he also works with the GMC as their IMG Advisor. He has been recognised as one of the most influential figures from the ethnic minority population across healthcare in the UK by the Healthcare Service Journal in 2020,2021, 2022 & 2023

He received an OBE for services to Diabetes care in 2021

Dr Anna Long

Dr Long completed an undergraduate master's in biology at the University of Bath (2006). Her type 1 diabetes research career began as a research technician measuring islet autoantibodies. Anna received her PhD from the University of Bristol in 2012. After this she was awarded a Fulbright scholarship by Diabetes UK. This enabled her to spend two years in Seattle, USA, studying the immune system of people 'at risk' of diabetes. In 2018, she was awarded an RD Lawrence Fellowship, jointly funded by Diabetes UK and the JDRF. With this funding she investigated why some people develop type 1 diabetes as adults when others are diagnosed when they are children. Anna has been a member of the international Islet Autoautoantibody Standardisation Program (IASP) organising committee since 2022. She is currently a Lecturer at the University of Bristol, with ongoing research aimed at improving identification of type 1 diabetes across all ages and ethnic groups.

Dr Loredana Marcovecchio

Dr Loredana Marcovecchio (MD, PhD) is a clinical scientist and consultant in paediatric endocrinology and diabetes at the Department of Paediatrics, University of Cambridge, UK. Since 2005, she has been actively involved in epidemiological studies, assessing risk factors for vascular complications in children and adolescents with type 1 diabetes. She also contributed to the design and conduct of the first randomized trial on ACE inhibitors and statins in adolescents with type 1 diabetes (AdDIT trial). More recently, she has been working in the field of prevention and treatment of type 1 diabetes, with a key role in the design and coordination of immunotherapy trials in newly diagnosed children and adolescents with type 1 diabetes, including the ITAD and MELT-ATG trials. Since 2021, she has been the clinical coordinator of the INNODIA clinical network. Her research has led to over 140 publications in high-impact journals and 5 prestigious research awards. Since 2020, she has been a member of ISPAD Guidelines Editorial Committee.

Dr Fulya Mehta

Fulya is a Paediatrician working in Diabetes and General Paediatrics at Alder Hey Children's Hospital in Liverpool. She is a National Speciality Advisor for Children and Young Adults (CYA) in the NHS England diabetes programme and prior to this was the clinical lead for the CYA workstream. Fulya has provided clinical leadership across key programme areas including tackling health inequalities with a focus on improving access to treatment technology, transition and young adult care and improving care and outcomes for young people living with type 2 diabetes. She has led on developing and delivering the CYA Diabetes 'Getting It Right First Time' programme and the CYA Diabetes Rightcare Toolkit, to support systems to improve diabetes care locally and reduce unwarranted variation.

Prof Parth Narendran

Parth's research interest focusses on understanding the autoimmune destruction of insulin secreting beta cells that lead to type 1 diabetes and exploring how this process can be modulated. He is part of a national effort to explore the feasibility and acceptability of early surveillance programmes for pre-type 1 diabetes and is also exploring which therapies are best tested in the prevention arena. He has developed an international reputation for exploring whether exercise can be used to modulate the autoimmune process in type 1 diabetes. He is the Chair of the MS Prevention Taskforce for the Multiple Sclerosis Society to explore treatment parallels across other conditions with similarities to type 1 diabetes.

Parth leads the Diabetes Research Unit and the Type 1 Diabetes clinical service at the Queen Elizabeth Hospital. He is the author of over 100 peer-reviewed publications including publications that have been cited by international bodies on Type 1 diabetes and its management. He has served on the Diabetes UK Research Committee and was previously on the Research Advisory Board of the Diabetes Research and Wellness Foundation and Regional Advisory Committee for the NIHR RfPB programme. He was previous chair of the Academic subcommittee of The Association of British Clinical Diabetologists having led and supported the setting up of its first research grant funding scheme and national Diabetes Update training programme for doctors specialising in diabetes and endocrinology.

Parth reviews for all the major national and international diabetes journals. He contributes to the NIHR Horizon Scanning, and NICE Medical Technology reviews for new therapies.

Amy Norman

My name is Amy Norman, and I'm a proud mother and someone who has lived with type 1 diabetes for many years. Managing this condition has taught me resilience, strength, and the importance of staying informed and proactive about my health. That journey became even more personal when my child was diagnosed at stage 2 prediabetes. It was a difficult and emotional time, but we were fortunate to have access to early intervention. Thanks to the incredible team at Birmingham Children's Hospital, my child received Teplizumab—a groundbreaking treatment that helps delay the onset of type 1 diabetes.

Going through this experience has deepened my commitment to raising awareness, supporting other families, and advocating for early detection and better treatment options. I'm passionate about sharing our story to inspire hope, encourage research, and build a stronger, more informed community for everyone affected by diabetes.

Prof Richard Oram

Professor Richard Oram is a clinician scientist with a record in bringing original ideas and approaches to type 1 diabetes research. His contributions showing persistence of endogenous insulin in many with longstanding type 1 diabetes (T1D). Professor Oram developed a type 1 diabetes genetic risk score (T1D GRS) that has rapidly been integrated into clinical care for classification of diabetes, with field changing impacts on type 1 diabetes population screening. In parallel, his study of extremely early onset T1D in babies is revealing novel insights about genetic, immune and phenotypic factors associated with very early onset diabetes, with critical advances relating to the role of β-cell stress, and immune checkpoints in causality of autoimmunity.

Chris Potts

Chris is a participant from the T1DRA screening study with a double positive auto-antibody result. He will be sharing his experience of screening and the downstream impact of receiving a positive result. He can provide a viewpoint that is infused by holding a Biology and Philosophy Degree, and a career that included Plumbing, Vaccine Manufacturing at Oxford's Clinical Biomanufacturing Facility, a Stimulation Engineer fracking wells in the North Sea and his current role as a self-employed spreadsheet guru.

Lauren Quinn

Dr Lauren Quinn is a diabetes and endocrinology resident doctor in the West Midlands and a clinical research fellow at the University of Birmingham. She is a PhD candidate, and her thesis is testing and developing a general population, paediatric type 1 diabetes screening programme in the UK to explore the feasibility and acceptability of screening.

Dr Marian Rewers

Dr. Rewers is a paediatric endocrinologist who has dedicated his research to finding the cause and prevention of type 1 diabetes (T1D) and its complications. In 2000, he joined the Barbara Davis Centre (BDC) as its clinical director and became its executive director in 2012. The Centre now serves >8000 children and adults with T1D and is the premier research institute in basic, translational, and clinical research.

Dr. Rewers has led NIH-funded projects: the Diabetes Autoimmunity Study in the Young (DAISY), The Environmental Determinants of Diabetes in the Young (TEDDY), the Celiac Disease Autoimmunity Research (CEDAR), the Coronary Artery Calcification in Type 1 (CACTI) and Insulin Resistance Atherosclerosis Study (IRAS). These large prospective cohort studies have expanded our knowledge of the causes and risks of autoimmunity, T1D, and diabetic complications. To translate these results to public health and prevention, Dr. Rewers initiated the Autoimmunity Screening for Kids (ASK) supported by the Breakthrough T1D and Helmsley Charitable Trust. ASK has screened 40,000 general population children for presymptomatic T1D and celiac disease, monitored >1,000 children with autoimmunity to provide access to prevention and prevent complications.

Dr. Rewers' recent program STOP T1D offers healthcare providers structured education in screening and monitoring to lower the barriers to screening for early T1D across the U.S. He has helped to train the next generation of physicians and scientists. Together, they have published more than 600 peer-reviewed articles in the area of diabetes.

Prof Alex Richter

Alex Richter is Professor of Clinical Immunology at the University of Birmingham and Honorary Consultant at University Hospitals Birmingham. She directs the Clinical Immunology Service, a UKAS-accredited NHS diagnostic laboratory delivering immunology and haematology testing for 135 NHS Trusts, supporting national myeloma and AML trials as well as industry-led validation studies. She leads national innovation programmes developing diagnostics for infectious and immune-mediated diseases, including a commercialised SARS-CoV-2 antibody assay, remote sampling for vaccine response and seroepidemiology, and point-of-care tests for Type 1 diabetes screening. She collaborates with decision-makers including MHRA and UKHSA and leads the diagnostics theme for the West Midlands Health Tech Innovation Accelerator. Her current focus is building a pipeline of affordable, accessible diagnostics to advance global equity in healthcare.

Prof Emily Simms

Emily K. Sims MD, MS is an Associate Professor of Pediatrics at Indiana University School of Medicine. Dr. Sims is an NIH-funded physician scientist specializing in pediatric endocrinology with a research focus on identification of mechanisms and biomarkers of intrinsic beta cell dysfunction contributing to development of type 1 diabetes (T1D), clinical measurements of beta cell function that can be used to understand T1D heterogeneity and responses to disease-modifying therapies, and application of therapeutics aimed at improving beta cell health in T1D.

Dr Kimber Simmons, MD, MS

Dr. Kimber Simmons is a paediatric endocrinologist and Associate Professor at the Barbara Davis Centre for Diabetes, University of Colorado. She directs the Centre's Early Type 1 Diabetes Clinic and Clinical Immunotherapy Program, where she leads real-world implementation of teplizumab and the care of individuals in the early stages of type 1 diabetes. Dr. Simmons also leads Ask the Experts (Asktheexperts.org), a national program supporting families and healthcare providers in interpreting and managing positive T1D screening results. As principal investigator for prevention and new-onset clinical trials, she is committed to advancing therapies that can delay, and ultimately prevent, the onset of type 1 diabetes.

Dr Nick Thomas

Dr Nick Thomas is a diabetes physician and academic clinical lecturer in Diabetes and Endocrinology at the University of Exeter. Type 1 diabetes is known to occur in adults but classically thought of as a disease of children and the majority of research is in this age group. Nicks research is looking to improve understanding of type 1 diabetes presenting in adults.

During his PhD he undertook research looking to better describe the pathophysiology and clinical features of type 1 diabetes presenting in adults and showed this is more similar than different from when the disease presents in children. As part of this he led a multicentre UK study DROPLeT looking to Define Rate Of Progression of Late onset Type 1 diabetes.

He is currently looking to understand how the disease first develops in adults and how we might identify adult cases before the onset of clinical symptoms. He is leveraging his experience from classifying adult diabetes at clinical diagnosis to guide management of adults with screen detected islet-autoantibodies.

Prof Tim Tree

Tim is an expert in human immunology, with a particular focus on understanding the role of T cells in health and disease. He studied Biochemistry at Imperial College London, where he also completed his PhD under the sponsorship of the World Health Organization, researching the immunobiology of river blindness. In 1995, he joined King's College London to begin a research programme exploring how the immune system contributes to the development of type 1 diabetes. Tim's current work centres on investigating how the balance of different immune cell populations affects the onset and progression of autoimmune and inflammatory diseases, and how immunotherapies can be used to slow their development.

Neil Wright

Neil Wright is a Consultant Paediatrican with a Sub-speciality interest in Endocrinology & Diabetes based at Sheffield Children's Hospital. He has been involved numerous guidelines regarding the management of type 1 Diabetes including DKA guidelines and CGM protocols. He was a Principal Investigator for the PROTECT study investigating Teplizumab for stage 3 diabetes with some experience of delivering such therapies.
